When you enroll through our links, we may earn a small commission—at no extra cost to you. This helps keep our platform free and inspires us to add more value.
Molecular Tumor Board 2023-2024
Master the Skills of Tomorrow with Coursera! From AI and Blockchain to Public Speaking and Psychology, Explore Courses Tailored for Your Success.
This Course Includes
coursera
0 (0 reviews )
Flexible schedule 
spanish
Online - Self Paced
course
Universitat de Barcelona
About Molecular Tumor Board 2023-2024
Se trata de un curso que nace a raíz de una de las sesiones formativas que realiza cada 15 días el Servicio de Oncología Médica del Hospital Clínic de Barcelona (HCB). En este curso se presentan casos clínicos simulando un MTB de tumores sólidos, con un objetivo principal, mejorar el conocimiento específico del impacto clínico del perfil molecular en tumores sólidos. Está destinado a médicos oncólogos y a estudiantes y profesionales vinculados a la oncología médica. Cada seminario que conforma el curso lo presenta un profesional de una patología diferente del Servicio de Oncología Médica del HCB.
What You Will Learn?
- Is there any role for presicion medicine in ampullary cancer? by Dra. Tamara Sauri Targeted therapy in upper tract urinary cancer by Dra. Laia Fernández What are the odds? Not everything that glitters is gold by Dr. Lucio Ghiglione Beyond HER2 amplification: do HER2 mutations play a role in Breast Cancer? by Dra. Isabel García Unexpected response to IO in a patient with advanced colorectal cancer by Dr. Juan Carlos Laguna Ataxia Teleangectasia Mutations (ATM) and advanced prostate cancer by Dra. Caterina Aversa dMMR/MSI-H facor predictivo en CCR localizado by Dr. Reinaldo Moreno Multiples tumors in a young patient ¿genetic or casuality? by Dra. Laura González Tackling KRAS G12C mutation in NSCLC by Dr. Francisco Javier Muñoz Presicion Medicine in NSCLC by Dra. Laura Mezquita Molecular characterization of agressive prostate cancer by Dra. Marta Garcia de Herreros Understanding the True Impact of Molecular Alterations by Dr. David Pesántez PARP inhibitors in somatic BRCA-mutant breast cancer: beyond germline pathogenetic variants by Dr. Francesco Schettini Personalized Treatment Strategies in Metastatic Colon Cancer by Dra. Mariam Rojas Beyond BRCAs in prostate cancer by Dr. Òscar Reig Targeted cholangiocarcinoma: myth or reality by Dr. Iván Victoria Rediscovering the uncharted EGFR uncommon mutations by Dra. Teresa Gorria.